BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22348467)

  • 1. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation.
    Stravitz RT; Shiffman ML; Kimmel M; Puri P; Luketic VA; Sterling RK; Sanyal AJ; Cotterell AH; Posner MP; Fisher RA
    Liver Int; 2012 Aug; 32(7):1138-45. PubMed ID: 22348467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
    Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
    J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir-emtricitabine therapy for the prevention of hepatitis B recurrence in four patients after liver transplantation.
    McGonigal KH; Bajjoka IE; Abouljoud MS
    Pharmacotherapy; 2013 Sep; 33(9):e170-6. PubMed ID: 23744810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation.
    Teperman LW; Poordad F; Bzowej N; Martin P; Pungpapong S; Schiano T; Flaherty J; Dinh P; Rossi S; Subramanian GM; Spivey J
    Liver Transpl; 2013 Jun; 19(6):594-601. PubMed ID: 23447407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
    Singer GA; Zielsdorf S; Fleetwood VA; Alvey N; Cohen E; Eswaran S; Shah N; Chan EY; Hertl M; Fayek SA
    Transplant Proc; 2015 Mar; 47(2):478-84. PubMed ID: 25769595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
    Wong SN; Chu CJ; Wai CT; Howell T; Moore C; Fontana RJ; Lok AS
    Liver Transpl; 2007 Mar; 13(3):374-81. PubMed ID: 17318855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
    Khemichian S; Hsieh MJ; Zhang SR; Limurti J; Kim J; Fong TL
    Dig Dis Sci; 2015 Sep; 60(9):2807-12. PubMed ID: 25939541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of tenofovir in the prevention of hepatitis B virus recurrence following liver transplantation.
    Hakim GD; Akarsu M; Karademir S; Unek T; Astarcıoğlu İ
    Turk J Gastroenterol; 2014 Dec; 25(6):685-9. PubMed ID: 25599782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
    Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
    Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
    Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
    Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
    Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
    Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
    Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
    Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
    J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
    Idilman R; Akyildiz M; Keskin O; Gungor G; Yilmaz TU; Kalkan C; Dayangac M; Cinar K; Balci D; Hazinedaroglu S; Tokat Y
    Clin Transplant; 2016 Oct; 30(10):1216-1221. PubMed ID: 27409074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
    Alvarez-Uria G; Ratcliffe L; Vilar J
    HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
    Angus PW; Patterson SJ; Strasser SI; McCaughan GW; Gane E
    Hepatology; 2008 Nov; 48(5):1460-6. PubMed ID: 18925641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade.
    Neff GW; O'brien CB; Nery J; Shire N; Montalbano M; Ruiz P; Nery C; Safdar K; De Medina M; Tzakis AG; Schiff ER; Madariaga J
    Liver Transpl; 2004 Nov; 10(11):1372-8. PubMed ID: 15497163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention and treatment of hepatitis B virus reinfection after liver transplantation].
    Liu J; Wu GC; Zhang ZT; Wu P; Zhang D; Sun MC; Gao DC; Wang Y; Jia JD; Wang BE
    Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):976-9. PubMed ID: 16194352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
    Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
    Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.